共 50 条
- [1] Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumorsONCOTARGETS AND THERAPY, 2017, 10 : 3177 - 3186Yao, James C.Chan, Jennifer A.Mita, Alain C.Kundu, Madan G.Resendiz, Karina HermosilloHu, KeRavichandran, ShobaStrosberg, Jonathan R.Wolin, Edward M.
- [2] Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET)PANCREAS, 2017, 46 (03) : 437 - 437Strosberg, JonathanChan, JenniferMita, AlainKundu, MadanHermosillo, KarinaHu, KeWolin, EdwardYao, James
- [3] Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET)JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Strosberg, Jonathan R.Chan, Jennifer A.Mita, Alain C.Kundu, MadanValera, Sue-zetteUnge, PeterDarstein, ChristelleHu, MikeWolin, Edward M.Yao, James C.
- [4] Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-Center, Open-Label, Dose-Escalation StudyNEUROENDOCRINOLOGY, 2016, 103 : 76 - 76Yao, J.Chan, J.Mita, A.Kundu, M.Valera, S. Z.Unge, P.Strosberg, J.Wolin, E.
- [5] Phase 1 Maximum-Tolerated Dose Study of Pasireotide LAR in Patients with Advanced Neuroendocrine TumorsPANCREAS, 2014, 43 (03) : 501 - 501Phan, Alexandria T.Wolin, Edward M.Chan, JenniferHuang, JerryHudson, MichelleHughes, GarethShen, GuoxiangStrosberg, Jonathan R.
- [6] A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Kristeleit, Rebecca SophieShapiro, GeoffreyLoRusso, PatriciaInfante, Jeffrey R.Flynn, MichaelPatel, Manish R.Tolaney, Sara M.Hilton, John FrederickCalvert, Alan HilaryGiordano, HeidiIsaacson, Jeffrey D.Borrow, JenniferAllen, Andrew R.Jaw-Tsai, Sarah S.Burris, Howard A.
- [7] Dose-Escalation of Octreotide-LAR in Patients With Neuroendocrine Tumors (NET)PANCREAS, 2014, 43 (03) : 497 - 497Kulke, Matthew H.Strosberg, Jonathan R.Lynn HuynhMei Sheng DuhSahai, VaibhavRademaker, Alfred W.Benson, Al B.
- [8] A phase I dose-escalation study of IMGN388 in patients with solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Thompson, D. S.Patnaik, A.Bendell, J. C.Papadopoulos, K.Infante, J. R.Mastico, R. A.Johnson, D.Qin, A.O'Leary, J. J.Tolcher, A. W.
- [9] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Berlin, JordanRamanathan, Ramesh K.Strickler, John H.Subramaniam, Deeps SureshHurwitz, HerbertKang, Yoon-KooKim, Tae-YouShepherd, Stacie PeacockXiong, HaoHetman, RobertNickner, CarolineDudley, Matthew W.Giranda, Vincent L.Lenz, Heinz-Josef
- [10] Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid TumorsONCOLOGIST, 2017, 22 (06): : 638 - +Cao, JunningJi, DongmeiChen, ZhiyuShen, WeinaWang, JinLi, BaoyueChi, HaidongLong, AmandaGao, LingLi, Jin